<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612881</url>
  </required_header>
  <id_info>
    <org_study_id>Fitostimoline pessaries</org_study_id>
    <nct_id>NCT04612881</nct_id>
  </id_info>
  <brief_title>Fitostimoline Vaginal Pessaries in Women With Hysterectomy. Randomized, Perspective, Monoscentric Study.</brief_title>
  <official_title>Clinical Verification of the Activity and Tolerability of Fitostimoline Vaginal Pessaries in Women With Hysterectomy. Randomized, Perspective, Monoscentric Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical evaluation of Fitostimoline vaginal pessaries in the treatment of hysterectomy. An&#xD;
      observational, randomized, perspective study performed on 60 women where 30 women are treated&#xD;
      with fitostimoline pessaries and 30 women are treated with the standard of care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2020</start_date>
  <completion_date type="Anticipated">September 18, 2021</completion_date>
  <primary_completion_date type="Actual">October 18, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TSS</measure>
    <time_frame>60 days</time_frame>
    <description>total symptom score (TSS) on a scale from 0 to 10 from worst to best</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vaginal Bleeding</condition>
  <arm_group>
    <arm_group_label>fitostimoline vaginal pessaries</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fitostimoline vaginal pessaries</intervention_name>
    <description>vaginal pessaries</description>
    <arm_group_label>fitostimoline vaginal pessaries</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>standard of care</description>
    <arm_group_label>fitostimoline vaginal pessaries</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        women aged between 30 and 80 years with hysterctomy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient aged between 35 and 80 years&#xD;
&#xD;
          -  patient undergoing hysterectomy&#xD;
&#xD;
          -  Willingness to understand the procedures and aims of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anamnestic or clinical data of metabolic or endocrine diseases (such as uncontrolled&#xD;
             diabetes mellitus) or any other local and / or systemic pathology potentially able to&#xD;
             interfere with the study parameters;&#xD;
&#xD;
          -  Concomitant treatment with antibiotics / antiseptics, NSAIDs, analgesics (excl.&#xD;
             Paracetamol)&#xD;
&#xD;
          -  Non-therapeutic use of psychoactive substances;&#xD;
&#xD;
          -  Abuse of drugs and / or alcohol / smoking;&#xD;
&#xD;
          -  Neurological disorders or psychiatric conditions potentially capable of affecting the&#xD;
             validity of the consent and / or compromising the patient's adherence to the study&#xD;
             procedures;&#xD;
&#xD;
          -  Known allergy, hypersensitivity or intolerance to the constituents of the preparations&#xD;
             under study;&#xD;
&#xD;
          -  Any condition, medical or otherwise, that could significantly reduce the possibility&#xD;
             of obtaining reliable data, achieving the objectives of the study, perfecting its&#xD;
             completion;&#xD;
&#xD;
          -  Presumption of poor reliability or collaboration;&#xD;
&#xD;
          -  Treatment with any preparation in the last 30 days prior to the start of the study;&#xD;
&#xD;
          -  Patients already enrolled in this study;&#xD;
&#xD;
          -  Center staff directly involved in the study and close relatives&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>barbara maglione</last_name>
    <phone>+393343293357</phone>
    <phone_ext>+393343293357</phone_ext>
    <email>barbara.maglione@farmadamor.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barbara Maglione</name>
      <address>
        <city>Napoli</city>
        <zip>80123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>barbara maglione</last_name>
      <phone>+393343293357</phone>
      <phone_ext>+393343293357</phone_ext>
      <email>barbara.maglione@farmadamor.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milan</investigator_affiliation>
    <investigator_full_name>Michele Vignali</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

